Form 4 for EW Edwards Lifesciences
Accepted 2026-05-04 19:30:46 ET · period of report 2026-05-01 · accession 0001225208-26-004909 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-05-04 19:30 | 2026-05-01+ | EW | Lippis Daniel J. | CVP, TAVR | M - OptEx | $59.26 | +2,038 | 34.7K | +6% | +$120.8K |
| DMT | 2026-05-04 19:30 | 2026-05-01+ | EW | Lippis Daniel J. | CVP, TAVR | S - Sale+OE | $83.49 | -2,038 | 33.7K | -6% | -$170.2K |
| DT | 2026-05-04 19:30 | 2026-05-03 | EW | Lippis Daniel J. | CVP, TAVR | F - Tax | $83.98 | -252 | 33.7K | -0.7% | -$21.2K |
| DMT | 2026-05-04 19:30 | 2026-05-01+ | EW | Lippis Daniel J. | CVP, TAVR | M - OptEx | $0.00 | -2,038 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-01 | M | A | 1,019 | $59.26 | 34,952.91 | D | — | — | (F1) The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 30, 2025. |
| 2 | Common | Common Stock | 2026-05-01 | S | D | 19 | $83.99 | 34,933.91 | D | — | — | (F1) The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 30, 2025. (F2) This transaction was executed in multiple trades at prices ranging from $83.980 to $84.095. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
| 3 | Common | Common Stock | 2026-05-01 | S | D | 1,000 | $82.99 | 33,933.91 | D | — | — | (F1) The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 30, 2025. (F3) This transaction was executed in multiple trades at prices ranging from $82.540 to $83.490. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
| 4 | Common | Common Stock | 2026-05-03 | F | D | 252 | $83.98 | 33,681.91 | D | — | — | |
| 5 | Common | Common Stock | 2026-05-04 | M | A | 1,019 | $59.26 | 34,700.91 | D | — | — | |
| 6 | Common | Common Stock | 2026-05-04 | S | D | 1,019 | $83.98 | 33,681.91 | D | — | — | |
| 7 | Derivative | Employee Stock Option (Right to Acquire) | 2026-05-01 | M | D | 1,019 | $0.00 | 1,019 | D | $59.26 · 2020-05-08 to 2026-05-07 | 1,019 Common Stock | |
| 8 | Derivative | Employee Stock Option (Right to Acquire) | 2026-05-04 | M | D | 1,019 | $0.00 | 0 | D | $59.26 · 2020-05-08 to 2026-05-07 | 1,019 Common Stock |